NCT06566261View on ClinicalTrials.gov

ABA-101 in Participants With Progressive Multiple Sclerosis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
Progressive Multiple Sclerosis
Interventions
BIOLOGICAL

ABA-101

ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy

Trial Locations (3)

21287

Johns Hopkins University, Baltimore

44195

Cleveland Clinic Mellen Center, Cleveland

08901

Rutgers, Robert Wood Johnson Medical School, New Brunswick

Sponsors

Lead Sponsor

Abata Therapeutics
All Listed Sponsors
lead

Abata Therapeutics

INDUSTRY